{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to Biohaven Pharmaceuticals Holding Company having its principal place of business in New Haven, Connecticut. The contemplated license would be for the inventions claimed in U.S. Utility Patent Number 8,859,585, issued October 14, 2014 (filed May 25, 2005), PCT Patent Application Number PCT/US2006/19335, filed May 18, 2006, U.S. Patent Application Number 14/478,442, filed September 5, 2014, European Patent Number 1896025, issued December 28, 2011 (and validated in Germany, France, and the United Kingdom), and Canadian Patent Number 2610025, issued July 22, 2014 (filed May 28, 2006). In addition, inventions claimed in any future applications claiming priority to or benefit of these patents and patent applications would also be subject to any license granted pursuant to this Notice. The patent rights in this invention have been assigned to the Government of the United States of America. The territory of the prospective Start-Up Exclusive Patent License Agreement may be worldwide and the field of use may be limited to use of scopolamine for treatment of neuropsychiatric indications.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2015/01/21/2015-00811.html","cfr_references":[],"citation":"80 FR 2951","comment_url":null,"comments_close_on":"2015-02-05","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before February 5, 2015 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[{"supporting_documents":[],"agency_name":"NIH","documents":[{"comment_count":0,"comment_start_date":"2015-01-21","updated_at":"2023-02-28T17:09:25.418-05:00","comment_url":"https://www.regulations.gov/commenton/NIH_FRDOC_0001-10363","allow_late_comments":null,"id":"NIH_FRDOC_0001-10363","comment_end_date":"2015-02-06","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"NIH_FRDOC_0001","title":"Recently Posted NIH Rules and Notices."}],"document_number":"2015-00811","effective_on":null,"end_page":2952,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2015/01/21/2015-00811.xml","html_url":"https://www.federalregister.gov/documents/2015/01/21/2015-00811/prospective-grant-of-start-up-exclusive-license-scopolamine-for-the-treatment-of-depression-and","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2015-00811?publication_date=2015-01-21","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2015-01-21/2015-00811/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":175,"last_updated":"2026-09-21 00:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-01-21/pdf/2015-00811.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-00811.pdf?1421761856","publication_date":"2015-01-21","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2015/01/21/2015-00811.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"NIH","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","document_id":"NIH_FRDOC_0001-10363","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2023-02-28T22:09:24Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":2951,"subtype":null,"title":"Prospective Grant of Start-up Exclusive License: Scopolamine for the Treatment of Depression and Anxiety","toc_doc":"Scopolamine for the Treatment of Depression and Anxiety","toc_subject":"Prospective Grants of Start-Up Exclusive Licenses:","topics":[],"type":"Notice","volume":80}